Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

医学 多西紫杉醇 内科学 乳腺癌 转移性乳腺癌 肿瘤科 临床终点 化疗 长春瑞滨 随机对照试验 癌症 外科 顺铂
作者
Debu Tripathy,Sara M. Tolaney,Andrew David Seidman,Carey K. Anders,Nuhad K. Ibrahim,Hope S. Rugo,Chris Twelves,Veronique C Dieras,Volkmar Müller,Yining Du,Sue L. Currie,Ute Hoch,Mary Ann Tagliaferri,Alison L. Hannah,Javier Cortés,ATTAIN Investigators,Daphne T. F. Tsoi,Susan Li Ling Chua,Elgene Lim,Craig R. Underhill
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (7): 1047-1047 被引量:25
标识
DOI:10.1001/jamaoncol.2022.0514
摘要

Importance: Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end point, treatment with etirinotecan pegol vs chemotherapy of the physician's choice for patients with advanced breast cancer demonstrated a significant improvement in overall survival (OS) for the prespecified patient subgroup with preexisting, pretreated, and nonprogressive BM. Objective: To compare clinical outcomes in patients with BM treated with etirinotecan pegol vs chemotherapy of the physician's choice in a confirmatory trial. Design, Setting, and Participants: This study was a phase 3, open-label, randomized clinical trial (ATTAIN) in patients with metastatic breast cancer and a history of stable pretreated BM who experienced disease progression while receiving chemotherapy in the metastatic setting. The trial took place at 47 sites in 10 countries, and patients were enrolled between March 7, 2017, and November 6, 2019. Interventions: Patients were randomized to receive etirinotecan pegol, 145 mg/m2, every 21 days or chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel). Main Outcomes and Measures: The primary end point was OS. Key secondary end points included progression-free survival, objective response rate, duration of response, and the clinical benefit rate. Results: A total of 178 female patients (9 [5.1%] Asian, 8 [4.5%] Black or African American, and 123 [69.1] White individuals) were randomized to receive treatment with etirinotecan pegol (92 [51.7%]; median [range] age, 53 [27-79] years) or chemotherapy (86 [48.3%]; median [range] age, 52 [24-77] years). Median OS was similar in both groups (etirinotecan pegol, 7.8 months; chemotherapy, 7.5 months; hazard ratio [HR], 0.90; 95% CI, 0.61-1.33; P = .60). Median progression-free survival for non-central nervous system metastases per blinded independent central review for etirinotecan pegol vs chemotherapy was 2.8 and 1.9 months (HR, 0.72; 95% CI, 0.45-1.16; P = .18) and 3.9 vs 3.3 months, respectively, for central nervous system metastases (HR, 0.59; 95% CI, 0.33-1.05; P = .07). Safety profiles between the groups were largely comparable. Conclusions and Relevance: The results of the ATTAIN randomized clinical trial found no statistically significant difference in outcomes between treatment with etirinotecan pegol and chemotherapy in patients with BM. However, this study represents one of the largest published trials dedicated to patients with breast cancer and BM and may help to inform further research. Trial Registration: ClinicalTrials.gov Identifier: NCT02915744.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
曾经的纸鹤完成签到,获得积分10
1秒前
3秒前
蟹堡王完成签到 ,获得积分10
3秒前
jjjj1021完成签到,获得积分10
4秒前
5秒前
孙毅航完成签到,获得积分10
5秒前
浩浩发布了新的文献求助10
5秒前
Mint完成签到 ,获得积分10
6秒前
yating完成签到,获得积分10
6秒前
6秒前
lnvvl发布了新的文献求助20
7秒前
zhao完成签到,获得积分10
7秒前
丘比特的应助被王乐乐采纳,获得10
7秒前
8秒前
8秒前
尘南浔发布了新的文献求助10
8秒前
i3utter发布了新的文献求助10
8秒前
zink完成签到,获得积分10
8秒前
书不尽风月完成签到,获得积分10
9秒前
10秒前
小蘑菇的应助被毕业就摆烂采纳,获得10
10秒前
11秒前
everything完成签到,获得积分10
11秒前
11秒前
11秒前
在水一方的应助被小冯在努力采纳,获得10
11秒前
叶林海发布了新的文献求助10
12秒前
dawei发布了新的文献求助10
12秒前
12秒前
13秒前
13秒前
13秒前
小二郎的应助被ke采纳,获得10
14秒前
Ava的应助被SHN采纳,获得10
15秒前
染染来信完成签到,获得积分10
15秒前
15秒前
寻寻123发布了新的文献求助20
15秒前
王鹤谞完成签到,获得积分20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193